Trial Profile
Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.
Status:
Not stated
Phase of Trial:
Phase III
Latest Information Update: 24 Nov 2021
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Filgrastim (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 08 Mar 2018 New trial record